MarketLens
Sign Up

What Drove TransMedics' Stellar Q4 2025 Performance

7 months ago
SHARE THIS ON:

What Drove TransMedics' Stellar Q4 2025 Performance

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

TransMedics Group Q2 Earnings Call Highlights

TransMedics Group (TMDX) reported record Q2 revenue, driven by growth in liver procedures, clinical services, and transplant logistics, which offset higher spending on product development, internation...
Stock News•2 months ago

Why CareDx Stock Jumped Today

CareDx stock rose today after strong demand for its non-invasive transplant monitoring tests, which are helping improve patient outcomes.
Stock News•3 months ago

Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics

Strata Critical Medical (SRTA) is rated a buy on expanding market share and operational efficiencies. Q1 2026 gross margin reached 21%, with management targeting 25% by 2027. Its asset-light model and...

Breaking News

View All →

Top Headlines

View More →
Stock News•57 minutes ago

Amazon's new Bee AI devices have a bystander problem, says former AWS security engineer

Stock News•1 hour ago

Here's Why ServiceNow (NOW) Fell More Than Broader Market

Stock News•1 hour ago

Salesforce (CRM) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•1 hour ago

1 Obvious Metric That Makes Nvidia a Top Stock to Buy Now

Stock News•1 hour ago

S&P 500 Snapshot: Stocks Slide Nearly 2% for the Week